(Alliance News) - BioPharma Credit PLC on Thursday said it has made a USD140.0 million investment in US biopharmaceutical company Insmed Inc for the development of therapies to treat neutrophil-mediated inflammatory diseases and rare pulmonary disorders.
The life sciences debt investment trust, through its fully owned subsidiary and together with BioPharma Credit Investments V LP, has entered into a definitive secured loan agreement with Insmed.
The company invested USD140.0 million, while BioPharma-V invested an additional USD210.0 million for a total of USD350.0 million.
BioPharma's total investment was limited to a 40% share of the transaction, by its requirement to hold cash for purposes of its discount control mechanism.
Nasdaq-listed Insmed has a market capitalisation of around USD2.5 billion. The Bridgewater Township, New Jersey-based company is the producer of Arikayce, a first-in-disease therapy approved in the US, Europe, and Japan to treat lung disease.
Alongside this transaction, Insmed announced the raising of USD150.0 million through a synthetic royalty sale and USD275.0 million through a follow-on equity offering. These financings will increase cash, cash equivalents, and marketable securities to approximately USD1.3 billion.
The loan will mature in October 2027 and will bear interest at a rate based upon the secured overnight financing right, subject to a SOFR of 2.5%, and a margin of 7.8% per annum.
A one-time additional consideration of 2.0% of the total loan amount is also payable upon funding of the loan.
BioPharma Credit shares were trading 5.5% lower at USD0.90 in London on Thursday afternoon.
By Holly Beveridge; hollybeveridge@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Biopharma Cred. (BPCR)